Optimization of clinical regimen of traditional Chinese medicine therapy for Parkinson's disease based on AMPK/SIRT3/GSK3ß /LC3 signaling pathway

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027798

Enrollment

Unknown

Registered

2019-11-29

Start date

2019-11-28

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

treatment group:Xifeng dingchan pill combined with madopar and other Western medicines

control group:madopar and other Western medicines

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Early stage: (1) qualified for TCM diagnostic criteria of fibrillation syndrome; (2) meet the western diagnostic criteria for Parkinson's disease; (3) aged >= 50 years, = 50 years, <= 75 years; (4) the improved Hoehn & Yahr is graded at level 2 ~ 3; (5) TCM syndrome differentiation: Yin deficiency of liver and kidney.

Exclusion criteria

Exclusion criteria: 1. Those who have been treated with levodopa or traditional Chinese medicine for tonifying liver and kidney without drug elution; 2. Have serious heart, liver, kidney disease or multiple organ failure, mental illness; 3. A history of drug or alcohol abuse; 4. Pregnant and lactating women; 5. Patients in other studies.

Design outcomes

Primary

Measure	Time frame
Routine blood test;liver function;renal function;Urine routine;	—

Secondary

Measure	Time frame
Routine;electrocardiogram;	—

Countries

China

Contacts

Public ContactXiaoming Shen

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

sxmdoc@163.com+86 0371-66231125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026